Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.20 EUR | +0.17% |
|
+1.72% | +40.86% |
06-17 | Bayer Files for FDA Approval of Gadoquatrane | DJ |
06-17 | Bayer Seeks US FDA Nod for MRI Contrast Agent Gadoquatrane | MT |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.53 | 3.73 | 4.65 | 4.04 | 1.74 | |||||
Return on Total Capital | 5.41 | 6.03 | 7.37 | 6.14 | 2.62 | |||||
Return On Equity % | -39.83 | 3.2 | 11.56 | -8.17 | -7.82 | |||||
Return on Common Equity | -40.03 | 3.15 | 11.56 | -8.2 | -7.87 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 62.01 | 61.33 | 62.78 | 58.55 | 55.3 | |||||
SG&A Margin | 33.54 | 33.15 | 31.6 | 30.89 | 35.97 | |||||
EBITDA Margin % | 23.99 | 18.92 | 25.04 | 23.79 | 14.71 | |||||
EBITA Margin % | 21 | 16.31 | 22.71 | 21.23 | 12.06 | |||||
EBIT Margin % | 16.61 | 16.04 | 17.98 | 16.37 | 6.8 | |||||
Income From Continuing Operations Margin % | -37.59 | 2.32 | 8.21 | -6.18 | -5.46 | |||||
Net Income Margin % | -25.35 | 2.27 | 8.18 | -6.17 | -5.48 | |||||
Net Avail. For Common Margin % | -37.61 | 2.27 | 8.18 | -6.17 | -5.48 | |||||
Normalized Net Income Margin | 8.08 | 8.2 | 8.5 | 7.32 | 3.62 | |||||
Levered Free Cash Flow Margin | 35.82 | -3.14 | 11.52 | 3.19 | 7.97 | |||||
Unlevered Free Cash Flow Margin | 38.09 | -1.31 | 12.83 | 4.68 | 10.58 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.34 | 0.37 | 0.41 | 0.4 | 0.41 | |||||
Fixed Assets Turnover | 3.42 | 3.61 | 3.85 | 3.53 | 3.48 | |||||
Receivables Turnover (Average Receivables) | 3.9 | 4.5 | 4.98 | 4.84 | 5.09 | |||||
Inventory Turnover (Average Inventory) | 1.46 | 1.53 | 1.51 | 1.43 | 1.52 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.97 | 1.11 | 1.08 | 1.27 | 1.19 | |||||
Quick Ratio | 0.65 | 0.7 | 0.67 | 0.78 | 0.7 | |||||
Operating Cash Flow to Current Liabilities | 0.13 | 0.17 | 0.2 | 0.17 | 0.25 | |||||
Days Sales Outstanding (Average Receivables) | 93.86 | 81.17 | 73.26 | 75.34 | 71.94 | |||||
Days Outstanding Inventory (Average Inventory) | 251.47 | 238.5 | 241.1 | 254.93 | 240.83 | |||||
Average Days Payable Outstanding | 138.17 | 130.81 | 123.37 | 136.5 | 134.65 | |||||
Cash Conversion Cycle (Average Days) | 207.16 | 188.86 | 190.99 | 193.77 | 178.12 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 136.05 | 123.23 | 107 | 136.06 | 127.36 | |||||
Total Debt / Total Capital | 57.64 | 55.2 | 51.69 | 57.64 | 56.02 | |||||
LT Debt/Equity | 108.13 | 109.99 | 86.81 | 115.41 | 110.78 | |||||
Long-Term Debt / Total Capital | 45.81 | 49.27 | 41.94 | 48.89 | 48.72 | |||||
Total Liabilities / Total Assets | 73.77 | 72.42 | 68.83 | 71.55 | 71.09 | |||||
EBIT / Interest Expense | 4.58 | 5.5 | 8.62 | 6.88 | 1.63 | |||||
EBITDA / Interest Expense | 6.88 | 6.75 | 12.35 | 10.32 | 3.71 | |||||
(EBITDA - Capex) / Interest Expense | 5.27 | 4.72 | 9.57 | 7.9 | 2.28 | |||||
Total Debt / EBITDA | 4.05 | 4.71 | 3.19 | 3.84 | 5.66 | |||||
Net Debt / EBITDA | 2.9 | 3.82 | 2.41 | 2.94 | 4.53 | |||||
Total Debt / (EBITDA - Capex) | 5.29 | 6.73 | 4.12 | 5.02 | 9.2 | |||||
Net Debt / (EBITDA - Capex) | 3.78 | 5.46 | 3.11 | 3.84 | 7.37 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -4.93 | 6.48 | 15.1 | -6.11 | -2.16 | |||||
Gross Profit, 1 Yr. Growth % | -5.34 | 5.31 | 17.82 | -12.44 | -7.78 | |||||
EBITDA, 1 Yr. Growth % | -8.11 | -16.83 | 16.81 | -10.81 | -34.78 | |||||
EBITA, 1 Yr. Growth % | -6.82 | -18.25 | 19.33 | -12.23 | -39.55 | |||||
EBIT, 1 Yr. Growth % | -1.5 | 1.42 | 22.02 | -14.49 | -54.65 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -745.68 | -106.57 | 307.63 | -170.62 | -13.46 | |||||
Net Income, 1 Yr. Growth % | -356.54 | -109.53 | 315 | -170.87 | -13.23 | |||||
Normalized Net Income, 1 Yr. Growth % | -7.2 | 6.08 | 12.09 | -19.19 | -58.93 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -750.76 | -106.42 | 314.58 | -170.94 | -13.15 | |||||
Accounts Receivable, 1 Yr. Growth % | -18.17 | 5.22 | 2.64 | -9.39 | -4.01 | |||||
Inventory, 1 Yr. Growth % | 2.92 | 3.22 | 20.52 | 2.28 | -3.44 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -6.16 | 8.23 | 7.77 | -2.58 | 1.01 | |||||
Total Assets, 1 Yr. Growth % | -7.23 | 2.94 | 3.86 | -6.9 | -4.65 | |||||
Tangible Book Value, 1 Yr. Growth % | 27.82 | 7.71 | -26.68 | -9.86 | -13.84 | |||||
Common Equity, 1 Yr. Growth % | -35.4 | 8.18 | 17.42 | -15.08 | -3.09 | |||||
Cash From Operations, 1 Yr. Growth % | -40.26 | 3.79 | 39.38 | -27.86 | 43.99 | |||||
Capital Expenditures, 1 Yr. Growth % | -8.75 | 7.98 | 12.95 | -6.71 | 0.98 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 156.07 | -109.27 | 377.87 | -74.03 | 426.27 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 130.29 | -103.65 | 260.61 | -65.78 | 187.2 | |||||
Dividend Per Share, 1 Yr. Growth % | -28.57 | 0 | 20 | -95.42 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.15 | 0.61 | 10.71 | 3.96 | -4.16 | |||||
Gross Profit, 2 Yr. CAGR % | 4.14 | -0.16 | 11.39 | 1.57 | -10.05 | |||||
EBITDA, 2 Yr. CAGR % | 17.91 | -12.15 | 12.55 | 2.07 | -26.53 | |||||
EBITA, 2 Yr. CAGR % | 21.98 | -12.24 | 14.49 | 2.34 | -30.16 | |||||
EBIT, 2 Yr. CAGR % | 27.08 | 0.65 | 14.38 | 2.14 | -41.07 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 234.59 | -34.88 | -48.26 | 69.67 | -21.82 | |||||
Net Income, 2 Yr. CAGR % | 148.83 | -50.56 | -37.12 | 71.49 | -21.58 | |||||
Normalized Net Income, 2 Yr. CAGR % | 28.68 | 0.11 | 12.53 | -4.83 | -37.49 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 229.49 | -35.35 | -48.4 | 71.49 | -21.51 | |||||
Accounts Receivable, 2 Yr. CAGR % | -9.68 | -7.22 | 3.92 | -3.57 | -6.74 | |||||
Inventory, 2 Yr. CAGR % | -0.77 | 3.07 | 11.54 | 11.03 | -0.62 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -4.88 | 0.83 | 8 | 2.46 | -0.8 | |||||
Total Assets, 2 Yr. CAGR % | -3.9 | -2.38 | 3.4 | -1.67 | -5.78 | |||||
Tangible Book Value, 2 Yr. CAGR % | 6.55 | 16.84 | -11.14 | -18.71 | -11.87 | |||||
Common Equity, 2 Yr. CAGR % | -18.52 | -16.41 | 12.71 | -0.14 | -9.28 | |||||
Cash From Operations, 2 Yr. CAGR % | -21.3 | -21.25 | 20.28 | 0.27 | 1.92 | |||||
Capital Expenditures, 2 Yr. CAGR % | -3.43 | -0.74 | 10.44 | 2.65 | -2.94 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 75.82 | -51.15 | -37.39 | 11.4 | -20.28 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 66.71 | -70.93 | -35.93 | 11.09 | -12.95 | |||||
Dividend Per Share, 2 Yr. CAGR % | -15.48 | -15.48 | 9.54 | -76.55 | -78.59 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 5.74 | 6.26 | 5.23 | 4.79 | 1.87 | |||||
Gross Profit, 3 Yr. CAGR % | 2.56 | 4.53 | 5.51 | 2.8 | -1.58 | |||||
EBITDA, 3 Yr. CAGR % | 3.36 | 5.3 | 5.53 | 4.15 | -14.25 | |||||
EBITA, 3 Yr. CAGR % | 2.4 | 7.14 | 7.29 | 4.78 | -16.51 | |||||
EBIT, 3 Yr. CAGR % | 0 | 18.43 | 9.33 | 3.81 | -24.89 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 68.58 | -9.74 | 20.01 | -42.61 | 35.56 | |||||
Net Income, 3 Yr. CAGR % | 12.68 | -16.13 | 0.48 | -34.56 | 36.66 | |||||
Normalized Net Income, 3 Yr. CAGR % | -3.41 | 21.38 | 6.16 | 0.77 | -24.06 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 62.04 | -11.33 | 20.11 | -42.62 | 36.7 | |||||
Accounts Receivable, 3 Yr. CAGR % | 3.64 | -4.97 | -4.05 | -0.72 | -3.71 | |||||
Inventory, 3 Yr. CAGR % | 18.72 | 0.54 | 8.59 | 8.36 | 5.98 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 15.33 | -0.66 | 3.1 | 4.35 | 1.98 | |||||
Total Assets, 3 Yr. CAGR % | 15.95 | -1.74 | -0.34 | -0.16 | -2.67 | |||||
Tangible Book Value, 3 Yr. CAGR % | 34 | 6.63 | 0.03 | -10.71 | -17.12 | |||||
Common Equity, 3 Yr. CAGR % | -6.04 | -10.45 | -6.38 | 2.56 | -1.14 | |||||
Cash From Operations, 3 Yr. CAGR % | -15.53 | -13.7 | -4.75 | 1.43 | 13.13 | |||||
Capital Expenditures, 3 Yr. CAGR % | 0.73 | 0.23 | 3.63 | 4.39 | 2.09 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 50.09 | -33.95 | 0.32 | -53.31 | 44.82 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 48.5 | -53.28 | -1.68 | -48.02 | 39.81 | |||||
Dividend Per Share, 3 Yr. CAGR % | -10.61 | -10.61 | -5.01 | -61.97 | -61.97 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -2.12 | 4.76 | 7.7 | 5.33 | 1.37 | |||||
Gross Profit, 5 Yr. CAGR % | 0.15 | 2.76 | 6.01 | 3.33 | -1.01 | |||||
EBITDA, 5 Yr. CAGR % | 0.11 | -1.32 | 7.15 | 9.66 | -8.7 | |||||
EBITA, 5 Yr. CAGR % | 0.55 | -2.3 | 7.31 | 11.6 | -9.64 | |||||
EBIT, 5 Yr. CAGR % | 0.3 | 1.52 | 5.82 | 12.87 | -14.62 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 31.13 | -22.92 | 5.1 | 16.18 | 1.1 | |||||
Net Income, 5 Yr. CAGR % | 20.62 | -26.08 | -10.77 | 11.65 | -9.01 | |||||
Normalized Net Income, 5 Yr. CAGR % | -2.39 | -0.07 | 3.05 | 11.53 | -14.11 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 26.63 | -25.7 | 2.52 | 15.44 | 1.32 | |||||
Accounts Receivable, 5 Yr. CAGR % | -0.77 | -1.73 | 3.75 | -4.41 | -5.13 | |||||
Inventory, 5 Yr. CAGR % | 5.09 | 6.12 | 15.79 | 4.61 | 4.81 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -1.1 | -0.66 | 12.37 | 0.58 | 1.52 | |||||
Total Assets, 5 Yr. CAGR % | 9.63 | 7.89 | 10.71 | -1.71 | -2.56 | |||||
Tangible Book Value, 5 Yr. CAGR % | 34.03 | 92.25 | 13.5 | -4.33 | -4.92 | |||||
Common Equity, 5 Yr. CAGR % | 4.7 | 1.71 | 1.05 | -6.46 | -7.55 | |||||
Cash From Operations, 5 Yr. CAGR % | -6.58 | -10.95 | -2.7 | -8.36 | -2.13 | |||||
Capital Expenditures, 5 Yr. CAGR % | -0.8 | 0.25 | 4.5 | 1.19 | 0.95 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 26.97 | -5.13 | 5.92 | -20.55 | -8.49 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 25.92 | -23.5 | 6.21 | -17.06 | -6.35 | |||||
Dividend Per Share, 5 Yr. CAGR % | -4.36 | -5.83 | -3.04 | -47.66 | -47.66 |
- Stock Market
- Equities
- BAYN Stock
- Financials Bayer AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition